Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy
- PMID: 11465092
- DOI: 10.1002/1521-4141(200105)31:5<1351::AID-IMMU1351>3.0.CO;2-9
Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy
Abstract
To characterize the immunological effects of intermittent IL-2 therapy, which leads to selective increases in CD4+ T lymphocytes in HIV-infected patients, 11 patients underwent extensive immunological evaluation. While IL-2 induced changes in both CD4+ and CD8+ cell number acutely, only CD4+ cells showed sustained increases following discontinuation of IL-2. Transient increases in expression of the activation markers CD38 and HLA-DR were seen on both CD4+ and CD8+ cells, but CD25 (a chain of the IL-2 receptor) increased exclusively on CD4+ cells. This increase in CD25 expression was sustained for months following discontinuation of IL-2, and was seen in naive as well as memory cells. IL-2 induced cell proliferation, but tachyphylaxis to these proliferative effects developed after 1 week despite continued IL-2 administration. It thus appears that sustained CD25 expression selectively on CD4+ cells is a critical component of the immunological response to IL-2, and that intermittent administration of IL-2 is necessary to overcome the tachyphylaxis to IL-2-induced proliferation.
Similar articles
-
Markers of lymphocyte homing distinguish CD4 T cell subsets that turn over in response to HIV-1 infection in humans.J Immunol. 1999 Sep 15;163(6):3539-48. J Immunol. 1999. PMID: 10477629
-
The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes.Clin Immunol. 1999 Feb;90(2):238-46. doi: 10.1006/clim.1998.4646. Clin Immunol. 1999. PMID: 10080836
-
Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.J Infect Dis. 2002 Sep 1;186(5):606-16. doi: 10.1086/342479. Epub 2002 Aug 9. J Infect Dis. 2002. PMID: 12195347 Clinical Trial.
-
Immunological effects of interleukin-2 therapy in human immunodeficiency virus-positive subjects.Clin Diagn Lab Immunol. 2001 Jul;8(4):671-7. doi: 10.1128/CDLI.8.4.671-677.2001. Clin Diagn Lab Immunol. 2001. PMID: 11427409 Free PMC article. Review. No abstract available.
-
Restoration of immunity with interleukin-2 therapy.AIDS Read. 1999 Nov;9(8):563-72. AIDS Read. 1999. PMID: 11082734 Review.
Cited by
-
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.Lancet Oncol. 2018 May;19(5):694-704. doi: 10.1016/S1470-2045(18)30148-7. Epub 2018 Apr 5. Lancet Oncol. 2018. PMID: 29628312 Free PMC article. Clinical Trial.
-
Effects of exogenous IL-2 administration on the homeostasis of CD4+ T lymphocytes.J Clin Immunol. 2004 Sep;24(5):503-14. doi: 10.1023/B:JOCI.0000040921.82055.91. J Clin Immunol. 2004. PMID: 15359109
-
CD4+ T-cell depletion in HIV infection: killed by friendly fire?Curr HIV/AIDS Rep. 2005 Feb;2(1):16-23. doi: 10.1007/s11904-996-0004-3. Curr HIV/AIDS Rep. 2005. PMID: 16091244 Review.
-
Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients.J Clin Invest. 2005 Aug;115(8):2139-48. doi: 10.1172/JCI23196. Epub 2005 Jul 14. J Clin Invest. 2005. PMID: 16025158 Free PMC article.
-
In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients.Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10632-7. doi: 10.1073/pnas.1000027107. Epub 2010 May 24. Proc Natl Acad Sci U S A. 2010. PMID: 20498045 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials